Health sciences

Insights on the Neurostimulation Devices Global Market to 2026 - Rise in Number of People Suffering from Hearing Loss is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Lundi, septembre 6, 2021

Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc.

Key Points: 
  • Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc.
  • the growth in the neurostimulation devices market may be attributed to the increasing prevalence of chronic neuromuscular disorder and the rising adoption of these devices by the physicians.
  • However, stringent regulations of the neurostimulation devices and lack of skilled professionals for performing the surgeries might restrain the market growth during the given time frame.
  • The market is expected to surge in the coming years, due to the rise in the number of people, suffering from hearing loss and other related concerns.

Global Smart Syringes Market 2021: Advance Production of Smart Syringes Underway to Meet Growing Needs of COVID-19 Vaccine Roll-out - ResearchAndMarkets.com

Retrieved on: 
Lundi, septembre 6, 2021

The global smart syringes market growth is registered on account of the growing prevalence of target diseases, the rise in number of vaccinations, and the growth of the geriatric population.

Key Points: 
  • The global smart syringes market growth is registered on account of the growing prevalence of target diseases, the rise in number of vaccinations, and the growth of the geriatric population.
  • The high cost of smart syringes, especially passive safety syringes as well as lack of awareness in developing nations, and alternative drug delivery methods are expected to hinder the global smart syringes market growth.
  • The Global Smart Syringes Market is segmented into product type such as Auto-disable syringes, Active safety syringes, and Passive safety syringes, by application such as Vaccination, Blood Specimen Collection, and Drug delivery.
  • North America is expected to hold highest market share in the global smart syringe market followed by Europe, and Asia-Pacific.

Global Medical Cannabis Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Lundi, septembre 6, 2021

Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.

Key Points: 
  • Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.
  • Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions.
  • Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market.
  • As a result, increasing disposable incomes are projected to create a positive impact on the demand for medical cannabis.

Distributors Announce Proposed Opioid Settlement Will Proceed to Next Phase

Retrieved on: 
Samedi, septembre 4, 2021

Under the proposed settlement agreement and process, all U.S. States, territories, and Washington DC were given 30 days to join the settlement, except West Virginia which settled previously with the companies.

Key Points: 
  • Under the proposed settlement agreement and process, all U.S. States, territories, and Washington DC were given 30 days to join the settlement, except West Virginia which settled previously with the companies.
  • After the conclusion of the political subdivision sign-on period, each company will independently determine whether a sufficient number of political subdivisions have joined for the settlement to proceed to implementation.
  • If the conditions are satisfied, the settlement would become effective 60 days after the distributors determine that there is sufficient participation to proceed.
  • During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the settlement.

Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

Retrieved on: 
Samedi, septembre 4, 2021

Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.

Key Points: 
  • Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.
  • In March 2016, Dr. Reddys had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co. Ltd.
    Erez Israeli, Chief Executive Officer, Dr. Reddys, said: Addressing unmet patient needs in oncology remains a prime focus area for us.
  • E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

HOPA Oncology Pharmacists Provide Chemotherapy Resources to Improve Patient Understanding and Outcomes

Retrieved on: 
Samedi, septembre 4, 2021

Oncology pharmacists are encouraged to use the education sheets in discussions with those undergoing cancer treatment and their caregivers.

Key Points: 
  • Oncology pharmacists are encouraged to use the education sheets in discussions with those undergoing cancer treatment and their caregivers.
  • The website is a joint effort dedicated to being forward-thinking and providing thorough education resources to improve treatment outcomes.
  • Oncology professionals and caregivers can download several IVE sheets from the site's library, which will continue to be updated by the collaborative.
  • The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care.

Adamis Announces Agreement to Sell Portion of US Compounding Business

Retrieved on: 
Mercredi, août 4, 2021

The transaction aligns with Adamis stated goal of focusing its efforts on the development of its prescription pharmaceutical pipeline.

Key Points: 
  • The transaction aligns with Adamis stated goal of focusing its efforts on the development of its prescription pharmaceutical pipeline.
  • Adamis expects to use the proceeds from the sale for general corporate purposes and to fund ongoing development of its pipeline.
  • Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, and radiation dermatitis.
  • Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis filings from time to time with theU.S.

Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

Retrieved on: 
Mercredi, août 4, 2021

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today reported business highlights and financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Total Revenue: Revenue was $13.4 million for the second quarter of 2021, which was derived from the Companys collaborations with Janssen and Ono Pharmaceutical.
  • R&D Expenses: Research and development expenses were $48.0 million for the second quarter of 2021, which includes $8.6 million of non-cash stock-based compensation expense.
  • ET to review financial and operating results for the quarter ended June 30, 2021.
  • As a result, investors, the media, and others interested in Fate Therapeutics are encouraged to review this information on a regular basis.

Natural Hormone Replacement Therapy Paves New Path for Treatment at Nova Vita Wellness Centers

Retrieved on: 
Mercredi, août 4, 2021

When compared to conventional hormone replacement therapy, studies show that pellets are superior for relief of menopausal symptoms, maintenance of bone density, and restoration of sleep patterns.

Key Points: 
  • When compared to conventional hormone replacement therapy, studies show that pellets are superior for relief of menopausal symptoms, maintenance of bone density, and restoration of sleep patterns.
  • Patients who did not respond well to other types of hormone therapy often have a high success rate with BHRT pellets.
  • Nova Vita Wellness Centers, with locations in Central and South Texas, recently added BHRT to its service offerings.
  • Nova Vita also offers Ketamine infusion therapya groundbreaking alternative therapy option for a variety of mental health conditions.

Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)

Retrieved on: 
Mercredi, août 4, 2021

CAMBRIDGE, Mass. and BASEL, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Positive results from clinical trials of Enzyvant’s investigational RVT-802 (allogeneic processed thymus tissue-agdc), engineered human thymus tissue implanted in 105 pediatric patients, were published today in The Journal of Allergy and Clinical Immunology.1

Key Points: 
  • These data suggest we are on the threshold of a brighter day for pediatric patients with congenital athymia.
  • Engineered human thymus tissue has been studied by researchers across 10 clinical studies at a single center for more than 25 years.
  • Ninety-five patients were included in the Efficacy Analysis Set (EAS) and 105 patients were included in the Safety Analysis Set.
  • Enzyvants lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency.